Overview
Ophthalmic device firm's preliminary Q4 revenue rises, beating analyst expectations
Company reports 10% increase in procedure volume compared to Q3 2025
Company appoints Mark Wilterding as new CFO, effective January 11, 2026
Outlook
Company to announce full-year 2026 guidance in February with audited 2025 results
Result Drivers
PROCEDURE VOLUME - 10% increase in procedure volume compared to Q3 2025 contributed to revenue growth
DEVICE SALES - Sale of 25 Light Delivery Devices expanded installed base to 1,134 units
MARKET POSITION - CEO Ron Kurtz noted strengthened position with 10% share of premium IOL market and adoption by over 25% of U.S. cataract surgeons
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $32.60 mln | $28.60 mln (9 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Rxsight Inc is $10.00, about 13.1% above its January 9 closing price of $8.84
Press Release: ID:nGNXz4kB2
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
